Sanofi Begins Building Chinese Plant For Flu Vaccines
This article was originally published in PharmAsia News
Construction has begun in China on a factory being built by Sanofi Pasteur, expected to completed within four years. Sanofi intends the $102 million plant in Shenzhen to produce seasonal influenza vaccines for Chinese as well as prepare for a flu pandemic. The plant expects to produce as many as 25 million doses of vaccine annually by 2012, and double that amount within another three years. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.